Market Place
Sourcing Support
Bicycle Therapeutics Presents At 2026 ASCO Annual Meeting
21 Apr 2026 //
FIRSTWORD PHARMA
Bicycle Pharma Updates Nuzefatide Pevedotin, EphA2 Pipeline
20 Apr 2026 //
PHARMIWEB
Bicycle Downsizes By 30% After Deprioritizing Lead Program
18 Mar 2026 //
BIOSPACE
Bicycle Therapeutics Presents At AACR Annual Meeting 2026
18 Mar 2026 //
PHARMIWEB
Bicycle Pumps Brakes on Lead Program, Deflates Headcount by 30%
17 Mar 2026 //
FIERCE BIOTECH
Bicycle Therapeutics Showcases 2025 Achievements, 2026 Strategy
12 Jan 2026 //
PHARMIWEB
Bicycle Gets Radiopharmaceutical Push From UK Uranium Deal
18 Dec 2025 //
FIERCE PHARMA
Bicycle Therapeutics Joins Jefferies London Healthcare Conference
12 Nov 2025 //
BUSINESSWIRE
Bicycle Therapeutics Updates Business Progress and Q3 Result
30 Oct 2025 //
BUSINESSWIRE
Bicycle Therapeutics Announces Q2 2025 Financial Results
08 Aug 2025 //
BUSINESSWIRE
Bicycle Therapeutics Poster Presentations at 2025 ASCO Meeting
22 May 2025 //
BUSINESSWIRE
Bicycle Therapeutics Reports Q1 2025 Financial Results
01 May 2025 //
BUSINESSWIRE
Bicycle Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
02 Apr 2025 //
BUSINESSWIRE
Bicycle Therapeutics at 24th Annual Needham Healthcare Conf.
01 Apr 2025 //
BUSINESSWIRE
Bicycle Therapeutics Announces New Board & Leadership Appointment
27 Mar 2025 //
BUSINESSWIRE
Bicycle Therapeutics Reports Progress & Q4 & Full Year 2024 Results
25 Feb 2025 //
BUSINESSWIRE
Bicycle Therapeutics Shares Zelenectide Data & 2025 Milestones
13 Jan 2025 //
BUSINESSWIRE
Bicycle Therapeutics to Present at Morgan Healthcare Conference
09 Jan 2025 //
BUSINESSWIRE
Bicycle Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
03 Jan 2025 //
BUSINESSWIRE
Bicycle Updates Zelenectide Pevedotin Program And NECTIN4 Strategy
12 Dec 2024 //
BUSINESSWIRE
Bicycle Expands Clinical Advisory Board with Oncology Experts
10 Dec 2024 //
BUSINESSWIRE
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq LR
02 Dec 2024 //
BUSINESSWIRE
Bicycle Therapeutics to Present Zelenectide Data at SABCS 2024
25 Nov 2024 //
BUSINESSWIRE
Bicycle Therapeutics to Attend Jefferies London Health Conference
12 Nov 2024 //
BUSINESSWIRE
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Rule
01 Nov 2024 //
BUSINESSWIRE
Bicycle Therapeutics Reports Q3 2024 Business Progress & Results
31 Oct 2024 //
BUSINESSWIRE
Bicycle Therapeutic Shows Imaging Data at Nuclear Medicine Congress
23 Oct 2024 //
BUSINESSWIRE
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
30 Oct 2023 //
PRESS RELEASE
Bicycle Therapeutics Selected to Participate in FDA Program
19 Oct 2023 //
BUSINESSWIRE
Bicycle Therapeutics Announces Expedited Development Plan for BT8009
11 Sep 2023 //
BUSINESSWIRE
Bicycle Therapeutics Announces Proposed $200 Million Public Offering of Shares
12 Jul 2023 //
PRESS RELEASE
Bicycle Therapeutics Announces Pricing of $200 Million Public Offering of Shares
12 Jul 2023 //
BUSINESSWIRE
Bicycle Therapeutics Appoints Alethia Young as Chief Financial Officer
23 Jun 2023 //
BUSINESSWIRE
Bicycle to Participate in TD Cowen Radiopharmaceutical Innovation Summit
13 Jun 2023 //
BUSINESSWIRE
Bicycle and Orano Present Preclinical Bicycle Radio-Conjugate Data at TIDES 2023
11 May 2023 //
BUSINESSWIRE
Bayer, Bicycle Partner on Targeted Radionuclide Therapies in Oncology
11 May 2023 //
BUSINESSWIRE
Bicycle Therapeutics Announces Collab With the German Cancer Research Center
04 May 2023 //
BUSINESSWIRE
Bicycle Therapeutics Reports 1Q 2023 FYR and Provides Corporate Update
04 May 2023 //
BUSINESSWIRE
Bicycle Announces PI Dose Escalation Results from Phase I/II Study of BT8009
14 Feb 2023 //
BUSINESSWIRE
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009
04 Jan 2023 //
BUSINESSWIRE
